Manorama Industries (541974) Q3 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 24/25 earnings summary
15 May, 2026Executive summary
Achieved record operational and financial performance in Q3 FY25, with revenue of INR 2,092 million (₹20,920.47 lakhs), up 112.5% YoY, driven by robust demand and commercialization of new fractionation facility.
EBITDA rose 253.4% YoY to INR 552 million, with margin expanding to 26.4% due to scale and operational efficiency.
PAT surged 296.8% YoY to INR 295 million (₹3,046.56 lakhs), with PAT margin at 14.1%.
Overseas expansion with seven new subsidiaries in West Africa and UAE to secure sourcing and expand client base.
Five new projects prioritized for the next 3–5 years, focusing on forward and backward integration.
Financial highlights
Q3 FY25 revenue grew 112.5% YoY to INR 2,092 million (₹20,920.47 lakhs), with exports contributing 73%.
EBITDA for Q3 FY25 was INR 552 million, margin at 26.4%, and PAT at INR 295 million (₹3,046.56 lakhs), PAT margin 14.1%.
Basic EPS for Q3 FY25 was INR 5.11; diluted EPS INR 5.09.
Employee benefit expenses in Q3 FY25 at INR 17.4 crore, including ESOP provision of INR 7.68 crore.
Revenue, EBITDA, and PAT CAGR from FY20–24 were 25%, 14%, and 15%, respectively.
Outlook and guidance
Confident of surpassing FY25 revenue guidance of INR 7,500 million (₹750 crore).
Capacity utilization for new plant expected to reach 60–65% by FY25 end and 75–80% in FY26.
EBITDA margin guidance raised to 23–25% for the full year, with further improvement expected.
CBE share in product mix targeted to reach 30% by March FY25.
Ongoing capex for forward and backward integration projects.
Latest events from Manorama Industries
- Q2 earnings grew as QIP funds supported working capital and expansion plans advanced.541974
Q2 26/27 - Manufacturing growth and capacity investment offset the exit from trading.541974
Q4 18/19 - FY23 growth accelerated as capacity expanded, despite input-cost and execution pressures.541974
Q4 22/23 - Revenue rose 37.8% and PAT 65.6% as expansion targets global specialty-fat demand.541974
Q4 21/22 - FY20 sales rose 84% as a new plant expanded capacity amid pandemic disruption.541974
Q4 19/20 - Revenue advanced, but pandemic pressure cut profit as capacity expansion continued.541974
Q4 20/21 - Q1 FY27 revenue and profit surged, supported by global expansion, capex, and strong margins.541974
Q1 26/27 - Revenue up 76.1%, EBITDA up 92.5%, and major CapEx and expansion plans approved.541974
Q4 25/26 - H1 FY26 revenue and profit surged YoY, margins remained strong, and FY26 guidance was upgraded.541974
Q2 25/26